LivaNova plc is a global medical technology company specializing in cardiovascular and neuromodulation solutions. Through its Cardiopulmonary segment, LivaNova offers a comprehensive portfolio of products designed for use in cardiac surgery and extracorporeal circulation. Key offerings include heart-lung machines, oxygenators, autotransfusion systems and proprietary mechanical circulatory support devices that aid clinicians in complex procedures such as cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO).
In its Neuromodulation segment, LivaNova develops and markets the VNS Therapy System, an implantable device that delivers targeted vagus nerve stimulation for the treatment of drug-resistant epilepsy and depression. The company’s neuromodulation therapies build on decades of clinical research, providing physicians with an alternative approach to patients who have not responded adequately to pharmaceuticals.
Formed in 2015 through the merger of Sorin Group and Cyberonics, LivaNova combines a rich heritage of innovation dating back to the 1950s with a forward-looking focus on next-generation medical technologies. Headquartered in London, the company maintains research, development and manufacturing operations across Europe, North America and the Asia-Pacific region, serving customers in over 100 countries.
Under the leadership of President and CEO Tony Milner, LivaNova continues to expand its global footprint and invest in clinical studies and device enhancements. The company’s strategic priorities include broadening its product portfolio, strengthening regulatory partnerships and driving adoption of its advanced therapies to improve patient outcomes worldwide.
AI Generated. May Contain Errors.
